SRZN Surrozen, Inc./DE Insider Trading

10% owner TCG Crossover GP II acquires 121,881 shares across 4 transactions totaling $3.0M in unprofitable biotech with -67.4% annual revenue decline

TCG Crossover GP II executed 4 separate purchases totaling 121,881 shares (121.9K shares) for $3,012,767.84 ($3.0M) at a blended average price of $24.72 between March 23–24, 2026, expanding its holdings by 19.8% to 736,547 shares (736.5K shares). The transaction occurs in Surrozen, Inc., a company with severe fundamental headwinds: latest-quarter revenue of $983,000.00 ($983.0K), a net loss of $-71,643,000.00 ($-71.6M), and annual revenue decline of -67.4%, with no profitability in its most recent full fiscal year. The current price of $26.14 lies 8.6% below the 52-week high of $28.60, reflecting a modest recovery from 90-day perspective (+14.2%). This is the insider's fifth transaction in Surrozen within an 11-day window (March 12–24), signaling sustained accumulation despite deteriorating top-line performance and ongoing operating losses.

TCG Crossover GP II buys 48,997 shares at $24.91 avg for $1.2M, raising stake to 675.6K shares (+7.8%)

TCG Crossover GP II, a 10% owner, executed 6 separate purchases totaling 48,997 shares for $1,220,361.80 across March 12–16, 2026, at a blended average price of $24.91. This represents a 7.8% increase in holdings from 626.6K to 675.6K shares. The timing coincides with SRZN trading near its 52-week range extremes (current $25.50 is -10.8% from the $28.60 high) and shortly after the insider's 5 prior trades at this ticker in early February, which achieved 30-day returns of +5.6% to +30.3%. The company remains unprofitable with a net income of $-71.6M and minimal revenue of $983.0K in the latest quarter, placing the valuation context on a loss-making profile. The accumulation pattern—multiple tranches over a short window—mirrors the insider's recent buying activity at this same ticker but lacks measurable 90-day outcome data to confirm execution timing at this stage.

TCG Crossover GP II LLC (10% owner) bought 18,856 shares for $444,844.45 at $23.59 blended average on Feb 11-12, 2026.

A significant 10% shareholder executed 4 separate purchases totaling 18,856 shares for $444,844.45 over two trading days (Feb 11-12, 2026) at a blended average price of $23.59, increasing holdings by 3.0% to 651,112 shares post-transaction. This purchase follows a cluster of 5 prior buys at SRZN within the preceding 10 days, suggesting a pattern of consistent accumulation despite the company's recent fundamentals: Surrozen reported revenue of $983,000.00 and net income of $-71,643,000.00 for the latest quarter, with a market cap of $209,828,386.08. The timing occurs while the stock has climbed 22.4% over 30 days and 88.6% over 90 days from its lows, yet remains 1.4% below its 52-week high of $24.84, indicating the insider is purchasing into a period of significant upward momentum rather than at depressed valuations.

TCG Crossover GP II, LLC bought 9,357 shares for $202.5K at avg. $21.65; post-transaction holdings 641.7K shares. Cluster pattern: 2 other insiders also bought within past 14 days.

TCG Crossover GP II, LLC, a 10% owner, executed 6 separate purchases totaling 9,357 shares for $202,534.17 across three trading dates (Jan 30–Feb 3, 2026), raising its holdings from 632,325 to 641,682 shares. The blended average purchase price of $21.65 sits 6.1% below the 52-week high of $24.59, and the company's stock has surged 85.8% over the past 90 days and 7.1% over the past 30 days. However, Surrozen remains deeply unprofitable—posting a net loss of $-71.6M against quarterly revenue of $983.0K—with a market cap of just $197.8M. The concurrent buying activity by 2 other insiders within the past 14 days mirrors this accumulation pattern, though the company's revenue-to-loss ratio underscores material fundamental stress that accompanies this multi-insider buying cluster.

10% owner COLUMN GROUP III GP, LP purchases 32,507 shares across 6 transactions for $641.6K at blended $19.74; stock now $17.98

COLUMN GROUP III GP, LP executed 6 separate purchases totaling 32,507 shares for $641,597.27 between January 15–20, 2026, at prices ranging from $19.60–$20.00, lifting holdings from 984,151 to 1,016,658 shares. The blended average price of $19.74 now sits 26.9% above the current price of $17.98, reflecting a post-transaction decline of 17.4% over 30 days. The company remains unprofitable with negative net income of $-71,643,000.00 on minimal quarterly revenue of $983,000.00, limiting the transaction's interpretive clarity regarding operational confidence. This series of purchases by the 10% owner represents material position accumulation in an early-stage, cash-flow-negative biotech context, but the subsequent price deterioration and absence of measurable outcomes from the insider's prior same-ticker trades (all filed within the prior week) prevents clear pattern assessment at this stage.

Director Kutzkey Tim purchased 32,507 shares for $641,597.27 across 6 transactions; stock down 26.9% from 52-week high at $17.98.

Tim Kutzkey, a Director at Surrozen, executed 6 separate purchases totaling 32,507 shares for $641,597.27 between January 13–20, 2026, at prices ranging from $19.60 to $20.00 per share (blended average $19.74). This accumulation increased his holdings from 984,151 to 1,016,658 shares (+3.3% vs pre-transaction). The company's latest quarter shows revenue of $983,000.00 and a net loss of $-71,643,000.00, with the company unprofitable over its most recent full fiscal year. At the current price of $17.98, the stock is trading 26.9% below its 52-week high of $24.59 and is down 17.4% over the past 30 days, despite a 31.7% gain over 90 days. Notably, Kutzkey has also executed 5 prior purchases at SRZN within the preceding week (January 6–14), all with outcomes not yet measurable. His cross-ticker track record shows 0% win rate on 14 prior buys at the 90-day mark, with an average 90-day return of -29.1%, though a 30-day average of +23.4%.

10% owner COLUMN GROUP III GP, LP buys 18.0K shares for $357.4K at $19.86 avg, adding 1.8% to holdings

COLUMN GROUP III GP, LP executed 4 separate purchases totaling 17,993 shares for $357,352.51 on January 13–14, 2026, at an average price of $19.86, increasing total holdings from 981.4K to 999.4K shares (+1.8%). The transactions occurred when SRZN traded near the $20.00 current level and within a 52-week range of $6.50–$24.59, roughly -18.7% from the 52-week high. Across this insider's cross-ticker open-market history, the track record shows 0.00% 90-day win rate with an average 90-day return of -23.6%, suggesting prior trades at other companies have not timed market recoveries well. At SRZN specifically, the insider has completed 5 prior trades, with the earliest measurable outcome (December 2025 purchase) showing a +10.3% 30-day return, though 90-day outcomes remain open. The company is unprofitable (net income of $-71.6M for the most recent full fiscal year) with minimal quarterly revenue ($983.0K), and the market cap stands at $171.4M.

Director Tim Kutzkey bought 17,993 shares of SRZN across 4 transactions for $357,352.51, raising holdings to 999,429 shares

Director Tim Kutzkey executed 4 separate open-market purchases totaling 17,993 shares (18.0K shares) for $357,352.51 at a blended average price of $19.86 on 2026-01-13 and 2026-01-14, increasing his holdings by 1.8% to 999,429 shares. The timing is notable given the stock's 90-day context: SRZN gained 47.3% over 90 days but has declined 18.7% from its 52-week high of $24.59 and fallen 10.6% over the past 30 days, creating a mixed signal around current valuation. The company remains unprofitable with net income of $-71.6M against revenue of $983.0K, raising questions about when or whether the business reaches sustainability. Kutzkey's cross-ticker track record shows 0% win rate on his 12 prior open-market buys measured at the 90-day mark, with an average 90-day return of -29.1%, though his prior purchases at SRZN show a single measurable 30-day outcome of +10.3% on a 2025-12-05 buy—limited evidence for inferring a pattern at this ticker.

COLUMN GROUP III GP LP (10% owner) bought 15,100 shares at $19.89 on 2026-01-06 for $300,296.72

COLUMN GROUP III GP LP executed 2 separate purchases totaling 15,100 shares for $300,296.72 at a blended average price of $19.89, increasing its stake from 974,793 to 989,893 shares (+1.5%). The purchase occurred at $19.89 per share versus a current price of $19.06 (−0.9% from transaction), well below the 52-week high of $24.59 (−19.1% decline). Notably, this insider accumulated shares during a sharp 30-day decline of −13.8% and immediately after executing 2 prior purchases on 2025-12-05 and 2025-12-04 at SRZN, a pattern of sustained accumulation across a compressed timeframe. However, this company is unprofitable with quarterly revenue of $983,000.00 and a full-year net loss of $-71,643,000.00, creating fundamental headwinds. The insider's cross-ticker track record shows 0% of prior buys achieved positive 90-day returns (avg −23.6%), though same-ticker purchases over the prior month have posted strong 30-day gains (+94.4%, +24.2%, +24.2%, +10.3%, +10.3%), and 90-day outcomes remain unmeasurable on these recent trades.

Director Tim Kutzkey purchased 15,100 shares of SRZN at $19.89 in 2 transactions; stock now -22.5% from 52-week high at $19.06.

Kutzkey executed 2 separate purchases totaling 15,100 shares for $300,296.72 at $19.89 on 2026-01-06, raising his holdings by 1.5% to 989,893 shares. The timing relative to recent price action is noteworthy: the stock has fallen 13.8% over the prior 30 days and is 22.5% below its 52-week high of $24.59, though it remains up 38.4% over the prior 90 days. His prior trades at SRZN (5 transactions in the last two months) showed mixed near-term returns—ranging from +10.3% to +94.4% over 30-day periods—but none yet have measurable 90-day outcomes. Fundamental context matters: the company reported $983,000 in quarterly revenue with a net loss of $71,643,000 and remains unprofitable, making this accumulation by a director worth monitoring closely against future quarterly results.